Federal Jury Finds Medtronic CoreValve Willfully Infringes Edwards' Transcatheter Valve Patent

Federal Jury Finds Medtronic CoreValve Willfully Infringes Edwards' 
Transcatheter Valve Patent 
IRVINE, CA -- (Marketwired) -- 01/15/14 --  Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced that a federal jury
today found that Edwards' United States Cribier transcatheter heart
valve patent is valid and that Medtronic CoreValve LLC willfully
infringes it. Edwards will move to enforce this verdict and intends
to seek a permanent injunction. The jury also awarded Edwards $394
million in damages, and the willfulness finding allows Edwards to
seek increased damages of up to three times that amount, in addition
to attorneys' fees.  
"As the long-time leader and innovator in heart valves, Edwards
invests in promising early technologies. As a result, Edwards holds a
number of important patents in transcatheter valve technology, and we
intend to continue to defend this intellectual property when it is
used by others without permission. We are proud of our long-standing
relationship with Prof. Cribier and other key innovators in
transcatheter heart valves, and we continue to work with them today
as we develop new transcatheter therapies for patients suffering from
heart valve disease," said Larry L. Wood, Edwards' corporate vice
president, transcatheter heart valves.  
The patent involved in this suit is part of the Cribier family of
patents and expires in December 2017. This case was tried in the U.S.
District Court for the District of Delaware and is directed at the
manufacture and sale of the CoreValve ReValving System in the U.S.,
as well as the worldwide sales of valves assembled in Medtronic's
Tijuana, Mexico facility using U.S. made components. 
In 2010, a federal jury found that Medtronic CoreValve LLC willfully
infringes on another Edwards patent, the U.S. Andersen transcatheter
heart valve patent, and awarded damages to Edwards. That finding was
upheld on appeal and an initial payment of $84 million was made by
Medtronic to Edwards in 2013. A decision on Edwards' request to
enjoin Medtronic's entrance into the U.S. market and additional
damages is still pending. Because some of the sales have been found
to infringe both the Andersen and Cribier patents, a portion of the
damages aw
arded in the Cribier case could be reduced.  
About Edwards Lifesciences
 Edwards Lifesciences is the global leader
in the science of heart valves and hemodynamic monitoring. Driven by
a passion to help patients, the company partners with clinicians to
develop innovative technologies in the areas of structural heart
disease and critical care monitoring that enable them to save and
enhance lives. Additional company information can be found at
www.edwards.com.  
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, Mr. Wood's statements and
statements regarding the potential for enhanced damages, duplicative
damages, attorneys' fees, and a permanent injunction. Forward-looking
statements are based on estimates and assumptions made by management
of the company and are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Our forward-looking
statements speak only as of the date on which they are made and we do
not undertake any obligation to update any forward-looking statement
to reflect events or circumstances after the date of the statement. 
Forward-looking statements involve risks and uncertainties that could
cause results to differ materially from those expressed or implied by
the forward-looking statements based on a number of factors,
including but not limited to, unanticipated outcomes from future
appeals and legal proceedings. These factors are detailed in the
company's filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended December
31, 2012. 
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks
of Edwards Lifesciences Corporation.  
Media Contact:  
Sarah Huoh
949-250-5070 
Investor Contact:  
David K. Erickson
949-250-6826 
 
 
Press spacebar to pause and continue. Press esc to stop.